Literature DB >> 22402598

Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging.

Tian Yang1, Chuan Lin, Jian Zhai, Song Shi, Min Zhu, Nan Zhu, Jun-Hua Lu, Guang-Shun Yang, Meng-Chao Wu.   

Abstract

PURPOSE: The BCLC staging classification has been widely endorsed to predict the prognosis of patients with HCC. However, its validity as a means of therapeutic instructions needs to be challenged. This study aimed to evaluate perioperative and long-term outcomes of surgical resection in patients with advanced hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer (BCLC) staging.
METHODS: This study used a prospectively maintained database consisting of a consecutive series of 511 Chinese patients with advanced HCC who underwent surgical resection in a hepatobiliary surgical center from 2001 to 2007. Mortality, morbidity, long-term overall survival (OS) and disease-free survival (DFS) were evaluated.
RESULTS: Hospital mortality was 2.3%, and overall morbidity was 31.3%. After a median follow-up period of 27.8 months (range, 0-112 months), the 1-, 3- and 5-year OS rate was 69.9, 41.2 and 30.5%, and the 1-, 3- and 5-year DFS rate was 48.2, 30.3 and 24.0%, respectively. The 1-, 3- and 5-year OS and DFS rates were significantly poorer in patients with vascular invasion and/or extrahepatic spread than those in patients without (both P < 0.001), and also poorer in patients with biliary invasion than those in patients without (both P < 0.05).
CONCLUSIONS: Surgical resection could be considered in part of patients with advanced HCC (BCLC stage C), with low mortality, acceptable morbidity and favorable survival benefits. These results imply that BCLC recommendations for treatment schedules of advanced HCC need to be re-evaluated.

Entities:  

Mesh:

Year:  2012        PMID: 22402598     DOI: 10.1007/s00432-012-1188-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  39 in total

1.  [Operative treatment of tumor thrombus in the portal vein].

Authors:  Meng-chao Wu
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2004-01-02

2.  Major achievements in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Lancet       Date:  2009-02-21       Impact factor: 79.321

3.  Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma.

Authors:  Xiao-Ping Chen; Fa-Zu Qiu; Zai-De Wu; Zhi-Wei Zhang; Zhi-Yong Huang; Yi-Fa Chen; Bi-Xiang Zhang; Song-Qing He; Wan-Guang Zhang
Journal:  Ann Surg Oncol       Date:  2006-05-23       Impact factor: 5.344

4.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

5.  Liver resection with portal vein thrombectomy for hepatocellular carcinoma with vascular invasion.

Authors:  Luca Aldrighetti; Carlo Pulitanò; Marco Catena; Marcella Arru; Eleonora Guzzetti; Jane Halliday; Gianfranco Ferla
Journal:  Ann Surg Oncol       Date:  2009-03-10       Impact factor: 5.344

6.  Hepatocellular carcinoma with bile duct thrombi: analysis of surgical treatment.

Authors:  Shu-You Peng; Jian-Wei Wang; Ying-Bin Liu; Xiu-Jun Cai; Bin Xu; Gui-Long Deng; Hai-Jun Li
Journal:  Hepatogastroenterology       Date:  2004 May-Jun

7.  Surgery of hepatocellular carcinoma complicated with cancer thrombi in bile duct: efficacy for criteria for different therapy modalities.

Authors:  Luo Xiangji; Tan Weifeng; Yi Bin; Liu Chen; Jiang Xiaoqing; Zhang Baihe; Shen Feng; Wu Mengchao
Journal:  Langenbecks Arch Surg       Date:  2009-05-07       Impact factor: 3.445

Review 8.  Hepatocellular carcinoma: current management and recent advances.

Authors:  Wan-Yee Lau; Eric C H Lai
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2008-06

9.  Cytoreductive surgery for hepatocellular carcinoma.

Authors:  W Y Lau; T W Leung; K L Leung; S Ho; N Leung; M Chan; J Lin; A K Li
Journal:  Surg Oncol       Date:  1994-06       Impact factor: 3.279

10.  Obstructive jaundice secondary to ruptured hepatocellular carcinoma into the common bile duct. Surgical experiences of 20 cases.

Authors:  M F Chen; Y Y Jan; L B Jeng; T L Hwang; C S Wang; S C Chen
Journal:  Cancer       Date:  1994-03-01       Impact factor: 6.860

View more
  37 in total

1.  Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study.

Authors:  Yong-Fa Zhang; Rong-Ping Guo; Ru-Hai Zou; Jing-Xian Shen; Wei Wei; Shao-Hua Li; Han-Yue OuYang; Hong-Bo Zhu; Li Xu; Xiang-Ming Lao; Ming Shi
Journal:  Eur Radiol       Date:  2015-09-22       Impact factor: 5.315

2.  Proposal of new classification for postoperative patients with hepatocellular carcinoma based on tumor growth characteristics.

Authors:  Cui-Hong Zhu; Xiao-Hui Liu; Rui Cao; Xiong-Zhi Wu
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

Review 3.  Adjuvant treatment strategy after curative resection for hepatocellular carcinoma.

Authors:  Wei Zhang; Bixiang Zhang; Xiao-Ping Chen
Journal:  Front Med       Date:  2021-03-23       Impact factor: 4.592

Review 4.  Current management of hepatocellular carcinoma: an Eastern perspective.

Authors:  Hyung Joon Yim; Sang Jun Suh; Soon Ho Um
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

Review 5.  Treatment of hepatocellular carcinoma: a systematic review.

Authors:  Shibo Lin; Katrin Hoffmann; Peter Schemmer
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

6.  Hypermethylation of ACP1, BMP4, and TSPYL5 in Hepatocellular Carcinoma and Their Potential Clinical Significance.

Authors:  Xueping Qiu; Bo Hu; Yifang Huang; Yunte Deng; Xuebin Wang; Fang Zheng
Journal:  Dig Dis Sci       Date:  2015-09-19       Impact factor: 3.199

7.  Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma.

Authors:  Jae Hyun Han; Dong Goo Kim; Gun Hyung Na; Eun Young Kim; Soo Ho Lee; Tae Ho Hong; Young Kyoung You
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

8.  Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.

Authors:  Feng Xia; Li-Li Wu; Wan-Yee Lau; Hong-Bo Huan; Xu-Dong Wen; Kuan-Sheng Ma; Xiao-Wu Li; Ping Bie
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

Review 9.  Grey zone in the Barcelona Clinic Liver Cancer Classification for hepatocellular carcinoma: Surgeons' perspective.

Authors:  Tian Yang; Wan-Yee Lau; Han Zhang; Bin Huang; Jun-Hua Lu; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

10.  Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.

Authors:  Jiang Li; Yu Hou; Xiao-Bei Cai; Bin Liu
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.